Here are four things to know.
1. Pfizer is working with financial advisors at JPMorgan Chase & Co., although the divestiture is still in a preliminary stage, the source said.
2. The drugs produce sales of more than $700 million and are valued at more than $2 billion, according to the report. About 40 percent of the sales occur in the U.S. and 45 percent occur in Europe.
3. Pfizer prefers to divest the medications through a single deal, as opposed to selling off each drug individually, reports Bloomberg.
4. Representatives from Pfizer and JPMorgan declined Bloomberg’s request for comment.
More articles on supply chain:
This week’s 5 must-reads for supply chain leaders
A new framework for measuring the true value of drugs: 5 takeaways
Bloomberg: Medtronic arranging sale of medical supplies business
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
